Abstract:Adjuvants, materials added to vaccines to enhance the resulting immune response, are important components of vaccination that are many times overlooked. While vaccines always include an antigen to tell the body what to vaccinate to, of equal importance the adjuvant provides the how, a significant factor in producing a complete response. The adjuvant space has been slow to develop with the first use of an adjuvant in a licensed vaccine occurring in the 1930s, and remaining the only adjuvant in licensed vaccines for the next 80 years. However, with vaccination at the forefront of protection against new and complex pathogens, it is important to consider all components when designing an effective vaccine. Here we summarize the adjuvant space in licensed vaccines as well as the novel adjuvant space in clinical trials with a specific focus on the materials utilized and their resulting impact on the immune response. We discuss five major categories of adjuvant materials: aluminum salts, nanoparticles, viral vectors, TLR agonists, and emulsions. For each category, we delve into the current clinical trials space, the impact of these materials on vaccination, as well as some of the ways in which they could be improved. Adjuvants present an exciting opportunity to improve vaccine responses and stability, this review will help inform about the current progress of this space. Translational impact statement In the aftermath of the COVID‐19 pandemic, vaccines for infectious diseases have come into the spotlight. While antigens have always been an important focus of vaccine design, the adjuvant is a significant tool for enhancing the immune response to the vaccine that has been largely underdeveloped. This article provides a broad review of the history of adjuvants and, the current vaccine adjuvant space, and the progress seen in adjuvants in clinical trials. There is specific emphasis on the material landscape for adjuvants and their resulting mechanism of action. Looking ahead, while the novel vaccine adjuvant space features exciting new technologies and materials, there is still a need for more to meet the protective needs of new and complex pathogens.

Next-Generation Adjuvants: Applying Engineering Methods to Create and Evaluate Novel Immunological Responses

Exploring structural engineering approach to formulate and characterize next-generation adjuvants

Vaccine adjuvants for infectious disease in the clinic

Current Progress in the Science of Novel Adjuvant Nano-Vaccine-Induced Protective Immune Responses

Adjuvant physiochemistry and advanced nanotechnology for vaccine development

A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms

Progress in Adjuvants

The scientific journey of a novel adjuvant (AS37) from bench to bedside

Vaccine Adjuvants: Selection Criteria, Mechanism of Action Associated with Immune Responses and Future Directions

Advances in Vaccine Adjuvants: Nanomaterials and Small Molecules.

[Research progress of new vaccine adjuvants].

New-age vaccine adjuvants, their development, and future perspective

Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells

Adjuvants and immune enhancement

Applications of Nanomaterials As Vaccine Adjuvants

What are the limits of adjuvanticity?

Re-inventing traditional aluminum-based adjuvants: Insight into a century of advancements

Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines

Natural Endogenous Adjuvants

Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease

Modern Subunit Vaccines: Development, Components, and Research Opportunities